ストックスクリーナーアプリを入手
12.02
1.72%
-0.21
アフターアワーズ：
11.60
-0.42
-3.49%
前日終値:
$12.23
開ける：
$12.38
24時間の取引高:
647.44K
Relative Volume:
0.64
時価総額：
$937.72M
収益：
$114.04M
当期純損益:
$-330.15M
株価収益率:
-2.5412
EPS:
-4.73
ネットキャッシュフロー:
$-274.85M
1週間 パフォーマンス:
-3.14%
1か月 パフォーマンス:
-16.93%
6か月 パフォーマンス:
+15.80%
1年 パフォーマンス:
+119.34%
1日の値動き範囲:
$11.83
$12.41
1週間の範囲:
$11.83
$13.18
52週間の値動き範囲:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
12.02 | 954.10M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-12 | 開始されました | Raymond James | Strong Buy |
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Institutional investors in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) see US$88m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 - GlobeNewswire
Phathom Pharmaceuticals sponsors Great GI Debates to showcase GERD treatment - Traders Union
(PHAT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Stop Loss: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Analysis Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Stock Market Recap: What is Phathom Pharmaceuticals Incs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Intraday Trade Alerts - baoquankhu1.vn
Momentum Shift: Can NTST maintain its current growth ratePortfolio Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Aug Final Week: What is Phathom Pharmaceuticals Incs book value per share2025 Technical Overview & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Millennium Management LLC Reduces Stake in Phathom Pharmaceuticals Inc - GuruFocus
What are the risks of holding Phathom Pharmaceuticals Inc.2025 Dividend Review & Advanced Technical Analysis Signals - mfd.ru
Is Phathom Pharmaceuticals Inc. a cyclical or defensive stockPortfolio Performance Summary & Growth Focused Entry Reports - mfd.ru
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AIGH Capital Management LLC Acquires Shares of 429,000 Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Aug Drivers: Is DENNs growth already priced inJuly 2025 Trade Ideas & Precise Buy Zone Tips - baoquankhu1.vn
H.C. Wainwright Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $26 - 富途资讯
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Investment Review: Is Alexanders Inc a momentum stockJuly 2025 Volume & Technical Pattern Based Signals - baoquankhu1.vn
Phathom Pharmaceuticals stock maintains Buy rating at Stifel on strong revenue outlook - Investing.com Canada
Breakeven On The Horizon For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - 富途牛牛
Cantor Fitzgerald reiterates Overweight rating on Phathom stock at $29 By Investing.com - Investing.com Canada
Bond Watch: Whats Phathom Pharmaceuticals Incs historical return2025 Technical Patterns & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
(PHAT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Phathom Pharmaceuticals: VOQUEZNA hits 1 million U.S. prescriptions milestone - Traders Union
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Legal Desire Media and Insights
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.6%Here's What Happened - MarketBeat
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Should Phathom’s US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? - Yahoo Finance
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - Улправда
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - Улправда
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - marketscreener.com
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - Улправда
What's Going On With Phathom Pharma Stock Thursday?Phathom Pharmaceuticals (NASDAQ:PHAT) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom Pharmaceuticals prices $130 million public offering - Investing.com
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):